Response Genetics, Inc. (RGDX)
Oncology Corporate Profile

(Journal of Clinical Investigation) July 26, 2010 - In the past few decades, developers of new anticancer therapies have moved away from cytotoxic drugs that simply target the proliferative hallmark of all cancer cells.

(James CCC) July 19, 2010 - Cancer researchers have discovered a previously unknown type of gene regulation and DNA behavior in breast cancer cells that may lead to better insight about environmental exposure to estrogen-like compounds.

(SmartBrief) July 6, 2010 - The combination of Biothera's experimental drug Imprime PGG(R) and Erbitux(R) (cetuximab) doubled the historical overall response rate and the time to progression of second- and third-line metastatic colorectal cancer patients treated with Erbitux monotherapy.

(MarketWatch) June 30, 2010 - Response Genetics Inc., a company focused on the development and sale of molecular diagnostic tests for cancer, today announced that it has expanded its ResponseDX: Lung(TM) genetic test panel to detect the presence of EML4-ALK gene variants in lung cancer patients.

(Innate Pharma) June 13, 2010 - Innate Pharma reports today final data on response rate from the Phase I/II clinical trial evaluating IPH 1101 associated low-dose IL-2 in combination with standard of care rituximab1, in patients with relapsing follicular Non-Hodgkin’s Lymphoma (“fNHL”; study “IPH 1101-202”).

(Yahoo! Finance) June 11, 2010 - Cell Therapeutics, Inc. today reported exploratory analyses of the data at study completion from the Company's pivotal PIX301 trial of Pixuvri(TM) (pixantrone dimaleate), the first randomized controlled trial in patients with relapsed or refractory, aggressive non-Hodgkin's lymphoma ("NHL").

(MarketWatch) June 7, 2010 - Myriad Pharmaceuticals, Inc. today announced the presentation of clinical data from two separate Phase 2a combination drug studies of AzixaTM (MPC-6827, verubulin) at the American Society of Clinical Oncology 2010 Annual Meeting in Chicago, IL.

(MSN Money) June 7, 2010 - Cell Therapeutics, Inc. announced today that updated phase II study results of OPAXIO (paclitaxel poliglumex) in patients with advanced esophageal cancer demonstrated that 38% (15/40) patients receiving OPAXIO in combination with cisplatin and concurrent radiation achieved a pathologic or endoscopic complete response.

(MSN Money) June 6, 2010 - Nektar Therapeutics today announced positive results from a Phase 2 clinical study evaluating single-agent NKTR-102 in women with platinum-resistant/refractory ovarian cancer.

(FOXBusiness) June 5, 2010 - Allos Therapeutics, Inc. today reported new analyses of data from the Company’s pivotal PROPEL trial of FOLOTYN® (pralatrexate injection) in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL).

(Clinical Data) June 3, 2010 - Clinical Data, Inc., today announced that data from a study of the Fc gamma 3A receptor (FCGR3A) in patients with follicular non-Hodgkin’s lymphoma (NHL) validates the use of genotyping for genetic variants in the Fc gamma receptors for predicting response to rituximab.

(BizJournals) June 3, 2010 - A study demonstrating the cost savings realized through the use of the ChemoFx® Drug Response Marker for assisting selection of treatment in recurrent ovarian cancer was published recently in the American Journal of Obstetrics and Gynecology (AJOG).

(Boston Biz Journals) May 26, 2010 - Findings published at the ASCO conference provide a new treatment strategy for patients and support favorable reimbursement coverage policies.

(Reuters) May 20, 2010 - Some patients in a small mid-stage clinical trial had a partial response to treatment with an experimental drug being developed by Eli Lilly and Co for advanced melanoma, the deadliest form of skin cancer, according to a summary of the data.

(MorningStar) May 17, 2010 - ImmunoCellular Therapeutics, a clinical-stage biotechnology company that is developing immune based therapies for the treatment of brain and other cancers, announced today that the Company and Torrey Pines Institute for Molecular Studies in San Diego, CA have identified several peptides which can generate CD-133 specific T-cells.

(Reuters) May 11, 2010 - Diagnostic tests maker Response Genetics Inc and GlaxoSmithKline Plc signed a deal that gives Glaxo rights to the U.S.-based firm's technology to assess certain gene mutations in tumor samples, sending Response Genetics' shares soaring.

(Reuters) May 11, 2010 - Diagnostic tests maker Response Genetics Inc and GlaxoSmithKline Plc signed a deal that gives Glaxo rights to the U.S.-based firm's technology to assess certain gene mutations in tumor samples, sending Response Genetics' shares soaring.

(ESMO) May 6, 2010 - An international team of researchers has discovered molecular evidence that may explain why some women with HER2 over-expressing breast cancer do not respond to drugs designed to target this important molecule.

(Stanford Univ. School of Medicine) April 29, 2010 - For the first time, researchers have used a healthy person's complete genome sequence to predict his risk for dozens of diseases and how he will respond to several common medications.

(Yahoo! Finance) April 30, 2010 - A new study, presented at the American Society of Breast Surgeons Annual Meeting in Las Vegas, found that Breast-Specific Gamma Imaging is highly accurate in monitoring the response of breast cancers to neoadjuvant chemotherapy.

(CNBC) April 19, 2010 - Bellicum Pharmaceuticals, Inc., a company developing therapeutic cancer vaccines, today announced the presentation of interim Phase I/II efficacy data for BPX-101, a novel dendritic cell vaccine for metastatic castrate resistant prostate cancer (mCRPC), in a Late Breaking poster at the American Association for Cancer Research (AACR) 101st Annual Meeting 2010 held in Washington, D.C.